 | |
- close
- close
|
Business Wire
Oct 14
Comment
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under
Sep 26
Comment
BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX
) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male testosterone deficiency (hypogonadism). The Company’s wholly-owned...
StreetInsider.com
Sep 23
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioSante+Pharmaceuticals+%28BPAX%29+and+Cell+Genesys+%28CEGE%29+Announce+Final+Exchange+Ratio+for+Merger/4964402.html for the full story.
Business Wire
Sep 22
Comment
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced merger between the companies. If the merger
FierceBiotech
Aug 10
Comment
BioSante Pharmaceuticals says that its planned merger with Cell Genesys will bring in between $20 million and $25 million, which can fund its development program for a gel to treat female sexual dysfunction. LibiGel is now in Phase III trials and...
Bloomberg
Aug 7
Comment
(Update2) BioSante Pharmaceuticals Inc., the
developer of a gel to treat female sexual dysfunction, aims to
fund clinical trials with cash from its planned acquisition of
Cell Genesys Inc., a developer of cancer vaccines.
Wall Street Journal
Jun 30
Comment
BioSante Pharmaceuticals agreed to acquire Cell Genesys for $38 million in stock, with the combined company expected to focus on female-sexual dysfunction and immunotherapy drugs.
MarketWatch
Jun 30
Comment
Stocks making notable moves in Tuesday's U.S. stock market include Apollo Group, H&R Block, Emulex, Schnitzer Steel and Vical.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
CEGE AT A GLANCE
References
| ||||||
|
|
